MGFA Study Web Content:

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

Study Purpose: To evaluate the efficacy and safety of a potential new therapy (subcutaneous infusion) for generalized myasthenia gravis

Recruitment Information:

Study Type: randomized

Status: recruiting

Target Patient: generalized myasthenia gravis

Eligible Ages: adults (at least 18 years old)

Link to appropriate websites
https://www.clinicaltrials.gov/ct2/show/NCT03052751?term=MG0002&rank=1

Inclusion and Exclusion Criteria:

Primary Inclusion Criteria: diagnosed with myasthenia gravis; known to have the antibodies that cause myasthenia gravis (AChR or MuSK); appropriate for treatment with plasma exchange or IVIg

Primary Exclusion Criteria: patient has participated in another study in past 30 days; patients with severe weakness affecting oropharyngeal or respiratory muscles, or who have myasthenic crisis; patients with only eye symptoms of
myasthenia gravis; pregnant women; quantitative myasthenia gravis (QMG) score of <10.5 at Baseline

Study Information:

Sponsor: UCB Biopharma

Principal Investigator: Click here to enter text.

Study Coordinator: Click here to enter text.

Type of Study: Multi-center

Study Duration: 18 week treatment

Single Center/Multi-center: Multi-center

Travel Funds Available: ☒ Y ☐ N

Find A Center Near You:

Recruitment is just starting in the MyMGVoice study. Sites will be enrolling patients soon, so please check with clinicaltrials.gov and search MG0002 for more information and updated site details. For participating sites you can also contact: UCB Cares at 1 877 822 9493